Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Simms

Showing results (101-110 of 107) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 107 results.
Plos One|May 16, 2013
Differential cytotoxic activity of a novel palladium-based compound on prostate cell lines, primary prostate epithelial cells and prostate stem cellsEngin Ulukaya, Fiona M Frame, Buse Cevatemre, et al.
British Journal of Cancer|November 14, 2013
HDAC inhibitor confers radiosensitivity to prostate stem-like cellsF M Frame, D Pellacani, A T Collins, et al.
Molecular Cancer|August 2, 2011
Regulation of the stem cell marker CD133 is independent of promoter hypermethylation in human epithelial differentiation and cancerDavide Pellacani, Richard J Packer, Fiona M Frame, et al.
FEBS Open Bio|April 26, 2022
ETS transcription factor ELF3 (ESE-1) is a cell cycle regulator in benign and malignant prostateLeanne K Archer, Fiona M Frame, Hannah F Walker, et al.
Cell Death and Differentiation|January 28, 2014
DNA hypermethylation in prostate cancer is a consequence of aberrant epithelial differentiation and hyperproliferationD Pellacani, D Kestoras, A P Droop, et al.
Hearing Research|January 4, 2023
Sex differences in body composition, voluntary wheel running activity, balance performance, and auditory function in CBA/CaJ mice across the lifespanMi-Jung Kim, Peter B Carmichael, Upal Bose, et al.
European Urology Oncology|June 4, 2019
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectivenessBeth S Woods, Eleftherios Sideris, Matthew R Sydes, et al.
Pageof 11

Showing results (101-110 of 107) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 107 results.
Plos One|May 16, 2013
Differential cytotoxic activity of a novel palladium-based compound on prostate cell lines, primary prostate epithelial cells and prostate stem cellsEngin Ulukaya, Fiona M Frame, Buse Cevatemre, et al.
British Journal of Cancer|November 14, 2013
HDAC inhibitor confers radiosensitivity to prostate stem-like cellsF M Frame, D Pellacani, A T Collins, et al.
Molecular Cancer|August 2, 2011
Regulation of the stem cell marker CD133 is independent of promoter hypermethylation in human epithelial differentiation and cancerDavide Pellacani, Richard J Packer, Fiona M Frame, et al.
FEBS Open Bio|April 26, 2022
ETS transcription factor ELF3 (ESE-1) is a cell cycle regulator in benign and malignant prostateLeanne K Archer, Fiona M Frame, Hannah F Walker, et al.
Cell Death and Differentiation|January 28, 2014
DNA hypermethylation in prostate cancer is a consequence of aberrant epithelial differentiation and hyperproliferationD Pellacani, D Kestoras, A P Droop, et al.
Hearing Research|January 4, 2023
Sex differences in body composition, voluntary wheel running activity, balance performance, and auditory function in CBA/CaJ mice across the lifespanMi-Jung Kim, Peter B Carmichael, Upal Bose, et al.
European Urology Oncology|June 4, 2019
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectivenessBeth S Woods, Eleftherios Sideris, Matthew R Sydes, et al.
Pageof 11